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The pathogenesis of Yo-mediated paraneoplastic cerebellar
degeneration (PCD) is unclear. We applied cerebrospinal
fluid and serum from PCD patients as well as CDR2 and
CDR2L antibodies to neuronal tissue, cancer cell lines, and
cells transfected with recombinant CDR2 and CDR2L to elu-
cidate which is the major antigen of Yo antibodies. We
found that Yo antibodies bound endogenous CDR2L, but
not endogenous CDR2. However, Yo antibodies can bind
the recombinant CDR2 protein used in routine clinical test-
ing for these antibodies. Because Yo antibodies only bind
endogenous CDR2L, we conclude that CDR2L is the major
antigen of Yo antibodies in PCD.
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Paraneoplastic cerebellar degeneration (PCD) is one ofthe most common paraneoplastic neurological syn-
dromes.1 In PCD patients, the immune system targets a tumor
antigen that is also expressed endogenously in the nervous sys-
tem.2 Among the most frequently detected onconeural anti-
bodies in PCD patients are Yo antibodies.3 Yo reactivity with
cerebellar degeneration-related (CDR) proteins present in
Purkinje cells is associated with Purkinje cell death4 and severe
cerebellar degeneration.5
Yo antibodies react with 2 proteins, CDR2 (RefSeq
NP_001793.1) and CDR2-like (CDR2L; RefSeq NP_
055418.2), that have 45% sequence identity.6 CDR2 has
previously been considered as the main Yo antigen.6–9 This
assumption is based in part on the finding that only the CDR2
gene is expressed in tumors obtained from PCD patients.6
However, recent studies have demonstrated that both
CDR2 and CDR2L are widely expressed in normal as
well as in malignant tissues10,11 and that the CDR2L
protein, but not CDR2, is highly expressed in PCD
tumors.12 Furthermore, CDR2L protein deposits are
detected in germinal centers of all Yo-mediated PCD
tumors with tertiary lymphoid structures,12 suggesting
an ongoing local immune response against CDR2L. In line
with this, we have shown that preabsorption with CDR2L
abolishes Yo antibody staining of human Purkinje cells
completely, whereas preabsorption with CDR2 does not.13
To determine which onconeural antigen is the major
target of Yo antibodies, we studied the reactivity of Yo anti-
bodies toward both native and recombinant CDR2 and
CDR2L proteins. Our findings show that Yo antibodies react
only to native CDR2L, and not to CDR2, suggesting that
CDR2L is the major target of these antibodies in vivo.
Materials and Methods
Patient Samples
Five sex- and age-matched cerebrospinal fluid (CSF)/serum patient
samples with Yo antibodies (PCD patients) and 5 without Yo anti-
bodies (controls) were obtained from the Neurological Research
Laboratory, Haukeland University Hospital (Regional Committees
for Medical and Health Research Ethics (REK), #2013/1480).10
Cerebellar Tissue
Cerebellar sections were cut from fresh frozen normal human tis-
sue (REK, #2013/1503) or paraformaldehyde (PFA)-perfused rat
brains (The Norwegian regulation of the use of animals in
research, #20157494) that required additional heat-induced epi-
tope retrieval prior to immunostaining.14
Cell Cultures
The OvCar3 (American Type Culture Collection [ATCC], #HTB-
161) and the HepG2 (ATCC, #HB-8065) cancer cell lines were
maintained and subcultivated on poly-D-lysine–coated coverslips
(Neuvitro, Vancouver, WA; #GG-18-1.5-pdl) according to the
manufacturer’s protocol. Cells were washed (2 × 0.1M phosphate-
buffered saline [PBS]), fixed (15 minutes, 4% PFA-PBS; Thermo
Fisher Scientific, Waltham, MA; #28908), and quenched (5 minutes,
50mM NH4Cl; Sigma-Aldrich, St Louis, MO; #254134) prior to
immunostaining.
From the 1Department of Clinical Medicine, University of Bergen,
Bergen, Norway; 2Department of Neurology, Haukeland University
Hospital, Bergen, Norway; and 3Neuro-SysMed - Centre of Excellence for
Experimental Therapy in Neurology, Departments of Neurology and
Clinical Medicine, Bergen, Norway
Address correspondence to Kråkenes, Department of Clinical Medicine,
Faculty of Medicine, University of Bergen, Jonas Lies vei 87, Bergen,
5021, Norway. E-mail: torbjornkrakenes@gmail.com
Received Nov 26, 2018, and in revised form May 9, 2019. Accepted for
publication May 27, 2019.
View this article online at wileyonlinelibrary.com. DOI: 10.1002/ana.25511.
© 2019 The Authors. Annals of Neurology published by Wiley Periodicals, Inc. on behalf of American Neurological Association.316
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use,
distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
Immunochemistry
Cancer cells and cerebellar sections were permeabilized (5 minutes,
0.5% Triton X-100-PBS; Sigma-Aldrich, #11332481001), washed
(3 × 15 minutes, 0.5% gelatin-PBS; Sigma-Aldrich, #G7041),
blocked (30 minutes, 10% SEABLOCK; Thermo Fisher, #37527),
incubated with primary antibodies (overnight, 4C), washed, incu-
bated with secondary antibodies (2 hours, room temperature),
and mounted (ProLong Diamond with DAPI; Thermo Fisher Sci-
entific, #P36962). Antibodies consisted of rabbit anti-CDR2
(AA270-392; Sigma-Aldrich, #HPA018151; cerebellar sections and
HepG2 cells), mouse anti-CDR2 (full-length; LSBio, Seattle, WA;
#C181958; OvCar3 cells), rabbit anti-CDR2L (AA116-465; Pro-
tein Technology,Wuhan, Hubei, P.R.C #14563-1-AP), antihuman
Alexa Fluor 488/594 (Thermo Fisher Scientific, #A-11013/#A-
11014), antirabbit Alexa Fluor 488/594 (Thermo Fisher Scientific,
#R37116/#R37117), antirabbit STAR635P (Sigma-Aldrich,
#53399-500UG), and antimouse Alexa Fluor 488/594 (Thermo
Fisher Scientific, #R37120/#R37121). A Leica (Wetzlar, Germany)
SP8 STED 3X confocal microscope equipped with a × 100 1.4
numerical aperture oil objective was used for imaging.
Immunoprecipitation
Following the Bio-Rad SureBeads immunoprecipitation protocol,
the proteins were immunoprecipitated from OvCar3 cell lysate by
using Protein G Magnetic Beads (Bio-Rad Laboratories, Hercules,
CA; #161-4023). Immunoprecipitated proteins were separated on
a 10% TGX gel (Bio-Rad, #456-1035) and transferred to a poly-
vinylidene difluoride (PVDF) membrane using the Trans-Blot
Turbo Transfer kit (Bio-Rad, #170-4274). Western blot analysis
was performed to detect the immunoprecipitated target proteins.
Antibodies consisted of rabbit anti-CDR2L, mouse anti-CDR2,
Yo-CSF, TidyBlot (Bio-Rad, #STAR209PA), and horseradish per-
oxidase antimouse IgG (Dako, Carpinteria, CA; #P0260).
Fluorescent Immunoblotting
The cerebellar and cancer cell lysates were obtained using a Total
Protein Extraction Kit (Millipore, Billerica, MA; #2140). Proteins
were separated on a 10% TGX gel and transferred to a low-
autofluorescence PVDF membrane. Antibodies consisted of rabbit
anti-CDR2L, rabbit anti-CDR2, Yo-CSF, antirabbit Alexa Fluor
488, and antihuman Alexa Fluor 647 (Thermo Fisher Scientific,
#A-21445). G:Box (Syngene, Frederick, MA) was employed for
visualization.
Recombinant DNA and Transfection
Full-length CDR2 (OriGene Technologies, Rockville, MD;
#RG204900) and CDR2L (OriGene Technologies, #RC206909)
were ligated into a pCMV6-AC-GFP vector (OriGene Technologies,
FIGURE 1: Yo antibodies bind to CDR2L, but not CDR2, in
cerebellar Purkinje cells. Scale bars = 10μm. (A) Sections of fresh
frozen human cerebellum. Upper row: Section stained with Yo
(cerebrospinal fluid [CSF]; green) and anti-CDR2L (red); the
antibodies colocalize in the cytoplasm (seen as yellow in the
merge image). Lower row: Section stained with Yo (CSF; green)
and anti-CDR2 (red); no colocalization is seen between Yo and
CDR2. (B) Sections of paraformaldehyde (PFA)-perfused rat
cerebellum. Upper row: Section stained with Yo (CSF; green) and
anti-CDR2L (red); CDR2L colocalize with Yo. Lower row:
Section stained with Yo (CSF; green) anti-CDR2 (red); no
colocalization is seen. (C) Sections of PFA-perfused rat cerebellum.
Upper row: Section stained with Yo (serum; green) and anti-
CDR2L (red); Yo and CDR2L colocalize in the Purkinje cells
(outlined) as well as in the stellate and basket cells (arrows). Lower
row: Section stained with Yo (serum; green) and anti-CDR2 (red);
no colocalization is seen between Yo andCDR2. These images are
a z-stack merge, as not all stellate/basket cells were in the same
focal plane as the Purkinje cells; thus, the cytoplasmic staining
found over or under the nuclei may appear nuclear although it is
not (eg, the Yo serum staining is not nuclear). (D) Fluorescent
immunoblot of rat cerebellar lysate. Anti-CDR2L and Yo (CSF)
stain the same band at 55kDa; anti-CDR2 does not. Secondary
antibody controlswere negative.
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#PS100010). Following polymerase chain reaction, correct CDR2
and CDR2L vector sequences were confirmed using BioEdit v7.2.5.
One Shot TOP10 Escherichia coli (Life Technologies, Carlsbad, CA;
#C4040-10) were used for amplification, E.Z.N.A. Plasmid DNA
Kit (Omega Bio-Tek, Norcross, GA, #D6942) for purification, and
Lipofectamine 3000 (Thermo Fisher Scientific, #L3000008) for
transfection.
Results
CDR2L and Yo Staining Overlap
In sections of human and rat cerebellum, CDR2L showed a
cytoplasmic staining pattern in Purkinje cell somas that over-
lapped completely with the Yo antibody staining from both
CSF and serum (Fig 1). CDR2L and Yo also colocalized in
the stellate and basket cells. In contrast, CDR2 primarily
stained the nuclei of these neurons and gave no overlap with
the Yo antibodies. Under denaturing conditions, immuno-
fluorescence blots of rat cerebellar lysate showed that
CDR2L and Yo were recognized at 55kDa, whereas CDR2
was only visible at 62kDa.
CDR2L and Yo Colocalize in Ovarian Cancer Cells
In OvCar3 cells, which express both CDR2 and CDR2L
endogenously, we found that CDR2L and Yo colocalized
in the cytoplasm, whereas CDR2 showed no colocalization
with Yo (Fig 2A). The coreactivity of the CDR2L and Yo
FIGURE 2: Yo antibodies bind to CDR2L, but not CDR2, in
OvCar3 cells. Scale bars = 10μm. (A) Upper row: OvCar3 cells
stained with Yo (cerebrospinal fluid [CSF]; green) and anti-
CDR2L (red); Yo and CDR2L colocalize, giving the same
granular, cytoplasmic staining pattern (seen as yellow in the
merge image). Lower row: OvCar3 cells stained with Yo (CSF;
green) and anti-CDR2 (red); Yo does not colocalize with CDR2.
(B) Fluorescent immunoblot (IB) of OvCar3 lysate. Anti-CDR2L
and Yo (CSF) stain the same 55kDa band; anti-CDR2 does not.
Secondary antibody controls were negative. (C) Immunoblot of
proteins immunoprecipitated (IP) from the OvCar3 lysate by
Yo (CSF) or CDR2L. The protein precipitated by Yo antibodies
was recognized by the CDR2L antibody on Western blot (i) and
vice versa (ii); no relationship was observed between Yo or
CDR2L and CDR2.
FIGURE 3: HepG2 cells, with a high endogenous level of CDR2,
are not stained by Yo antibodies. However, Yo antibodies
are able to bind recombinant CDR2. Scale bars = 10μm.
(A) Untransfected HepG2 cells (first row) and HepG2 cells
transfected with a vector expressing recombinant CDR2L-
GFP (second and third row; green) were incubated with Yo
(cerebrospinal fluid [CSF]; red), anti-CDR2L (first and second row;
magenta), and anti-CDR2 (third row; magenta). Nuclei were
stained with DAPI. Only upon expression of recombinant CDR2L
was Yo and CDR2L antibody staining observed. The CDR2
antibody did not bind the recombinant CDR2L protein.
(B) Untransfected HepG2 cells (first row) and HepG2 cells
transfected with a vector expressing CDR2-GFP (second and
third row; green) were incubated with Yo (CSF; red), anti-CDR2
(first and second row; magenta), and anti-CDR2L (third row;
magenta). Native CDR2 is present in untransfected HepG2 cells,
but no Yo staining was found.When recombinant CDR2-GFPwas
present, both the Yo and CDR2L antibodywere able to bind.
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antibodies was confirmed by both fluorescent Western blot-
ting and immunoprecipitation (see Fig 2B, C).
Yo Antibodies Detect Recombinant CDR2 and
CDR2L
Yo and CDR2L staining was absent in untransfected HepG2
cells, whereas CDR2 was present in the nuclei of these cells
(Fig 3). In HepG2 cells transfected with recombinant CDR2
or CDR2L linked to green fluorescent protein (CDR2-GFP
and CDR2L-GFP), however, Yo antibodies colocalized with
both CDR2L-GFP and CDR2-GFP. Similar results were
obtained for all PCD samples tested.
Discussion
We demonstrate that Yo antibodies in the CSF and serum
of PCD patients consistently react with CDR2L in human
FIGURE 4: Proposed hypothesis of how Yo antibodies are able to bind both recombinant CDR2 and CDR2L, but only CDR2L under
native conditions. (A) Illustration of the initial, polyclonal response of Yo antibodies toward CDR2L in the tumors of paraneoplastic
cerebellar degeneration patients. (B) A tumor cell with the polyclonal Yo antibodies targeting the CDR2L protein; CDR2 is
unaffected, as the epitope that is common to CDR2L (blue) is hidden by post-translational modifications or a partnering molecule
(white fold covering the blue epitope). (C) The Yo antibodies also bind to CDR2L in cerebellar Purkinje cells; however, they do not
bind CDR2, as the common epitope (blue) is hidden here as well (by modifications or partnering molecules; white fold). (D) When
patient sera or cerebrospinal fluid is applied to a line blot with recombinant CDR2 attached, binding of the common epitope (blue)
is possible, as it is not hidden by post-translational modifications or partnering molecules in the recombinant version.
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and rat brain tissue as well as in cultured cancer cells.
Despite sequence homology between CDR2 and CDR2L,
Yo antibodies did not cross-react with endogenously
expressed CDR2. These findings were confirmed by using
HepG2 cells that express CDR2 endogenously, but not
CDR2L; Yo antibodies were not able to bind the endoge-
nous CDR2 in these cells either. We therefore conclude
that CDR2L is the major antigen of Yo antibodies under
native conditions. This result indicates that previous
research on Yo-mediated PCD has focused on a protein
that is not the major antigenic target of Yo antibodies.
CDR2L and Yo antibodies gave a granular, cytoplas-
mic staining pattern that colocalized in both human and
rat Purkinje cells, as well as in stellate and basket cells. In
contrast, CDR2 reactivity primarily occurred in the nuclei
of these neuronal cells, where Yo antibody staining was
absent. In the human cancer cell lines OvCar3 and HepG2,
we found strong staining of CDR2 in the nuclei, as well as
some cytoplasmic staining. Similar CDR2 staining has also
been found in other cancer cell lines and tissues.15
We found that none of our PCD patient samples
cross-reacted with endogenous CDR2. Thus, CDR2L-
exclusive epitopes appear to be the major targets of Yo anti-
bodies under native conditions. Furthermore, we observed
competitive binding between the CDR2L and the Yo anti-
bodies, whereas the CDR2 antibody staining was not
affected by high Yo antibody concentrations (data not
shown). This is in line with our previous results showing that
the reactivity of Yo antibodies in the Purkinje cells disappears
completely when preabsorbed with recombinant CDR2L
protein, but only partially with recombinant CDR2.13
In routine clinical testing for onconeural antibodies,
line blots and cell-based assays use recombinant CDR2 as
the antigen target for Yo antibodies (Euroimmun, www.
euroimmun.com; ravo Diagnostika, www.ravo.de). Because
we did not find any reactivity of Yo antibodies toward
native CDR2, we investigated this further by transfecting
HepG2 cells with CDR2 and CDR2L linked to green fluo-
rescent protein. Our results showed that Yo antibodies did
bind recombinant CDR2, meaning that the protein can
still be used for clinical diagnostic purposes. However, line
blot and cell-based assays using CDR2L may be more sensi-
tive for detecting Yo antibodies.
Whereas Yo antibodies are able to bind recombinant
CDR2, they appear unable to access this epitope on endoge-
nous CDR2, likely because it is hidden by post-translational
modifications or by partnering molecules (Fig 4). A recent
study did not find any common linear epitopes detected by
Yo antibodies for CDR2 and CDR2L.16 This suggests that
any common epitope is likely conformational, a feature that
can be elucidated once the 3-dimensional structures of these
proteins are established.
Our present results strengthen the hypothesis that
CDR2L is the major target of Yo antibodies. This is in line
with the recent findings that CDR2L expression was detected
in all samples of ovarian cancers from PCD patients, whereas
CDR2 was only weakly expressed in 40% of the tumors.12
Furthermore, CDR2L deposits were found in germinal cen-
ters of all Yo-mediated PCD tumors with tertiary lymphoid
structures, suggesting a humoral immune response against
CDR2L.12 Thus, Yo antibodies targeting CDR2L in tumor
cells, with binding of CDR2L in Purkinje cells as an unfortu-
nate side effect, likely contributes to the development of
PCD. CDR2L should therefore be included in future research
into the pathogenesis of Yo-mediated PCD.
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